Over a six-year period, Medicare may have spent $380 million on organs that were not ultimately used in covered enrollee transplants, according to a September HHS Office of Inspector General report, revealing a significant OIG Medicare $380 million unused organs finding tied to conflicting federal guidance.
The Regulatory Conflict Behind This OIG Medicare $380 Million Unused Organs Finding
Under federal law, Medicare can only reimburse certified transplant centers for organs used in covered transplants. However, CMS guidance relies on the assumption that any organ a certified transplant center surgically removes and then passes onto an organ procurement organization, or another transplant center, will end up used in a Medicare-covered transplant.
Why This Assumption Created a Payment Gap
This built-in assumption within CMS guidance effectively allowed reimbursement to proceed automatically once an organ was removed and transferred, regardless of whether that organ was ultimately used in a Medicare-covered transplant, creating a structural gap between what the law technically permits and what the agency’s own guidance has been allowing in practice.
The Sample Data Behind This OIG Medicare $380 Million Unused Organs Estimate
Looking at 180 reported Medicare-usable organs, Medicare reimbursed centers $2.8 million for 43 organs not used in covered transplants, as well as 12 organs not transplanted at all. Furthermore, two certified transplant centers could not supply documentation to back five organs, resulting in $154,210 in improper Medicare reimbursement.
How OIG Extrapolated to the $380 Million Figure
OIG extrapolated its $380 million figure from the sample. The report said CMS guidance and federal law are in conflict, meaning this national estimate represents a statistical projection derived from the smaller audited sample rather than a direct accounting of every improper payment made during the six-year period.
Why This Conflict Wasn’t Resolved Earlier
CMS even acknowledged this discrepancy in 2021 rulemaking, but that was not incorporated in a final rule. This gap between CMS’s own 2021 acknowledgment of the problem and its failure to formally resolve it through rulemaking suggests the conflict identified in this OIG report has been a known issue within the agency for several years without corrective action being finalized.
Why This Delay Matters for the Broader Finding
Given that CMS recognized this discrepancy nearly five years before OIG’s current report, the estimated $380 million in improper payments accumulated during a period when the agency was already aware its guidance conflicted with federal statutory requirements, raising questions about why the issue remained unaddressed for so long.
OIG’s Recommendations Within This Medicare $380 Million Unused Organs Report
The office recommended CMS have Medicare administrative contractors recover the $154,210. The office also called on CMS to update Medicare guidance, aligning it with federal statutory requirements. While CMS agreed with OIG’s first recommendation, the agency did not take a definitive position with the second.
Why CMS’s Mixed Response Matters
CMS’s willingness to recover the specific $154,210 in documented improper payments, paired with its reluctance to commit to the broader guidance update, suggests the agency may be treating this as an isolated compliance issue rather than fully acknowledging the systemic conflict OIG’s report identifies between its guidance and federal law.
What This OIG Medicare $380 Million Unused Organs Finding Means Going Forward
With CMS declining to take a definitive position on updating its guidance to align with federal statutory requirements, the underlying conflict OIG identified may persist unless the agency takes further action, potentially exposing Medicare to continued improper payments for organs that are removed but never transplanted into covered enrollees. Given that CMS acknowledged this same discrepancy in 2021 without finalizing a rule change, transplant centers and organ procurement organizations should watch for whether this new OIG report finally prompts the regulatory update that earlier rulemaking efforts failed to complete.
What to Watch Going Forward
As CMS considers whether to update its Medicare guidance in response to OIG’s recommendation, industry observers will likely watch whether the agency finally aligns its organ reimbursement policy with federal statutory requirements, or whether this conflict remains unresolved as it has since at least 2021. Given the substantial gap between the audited sample and the extrapolated $380 million figure, this OIG Medicare $380 million unused organs finding may prompt renewed scrutiny of how CMS oversees transplant center reimbursement more broadly, particularly if Medicare administrative contractors begin pursuing recovery of the specific improper payments OIG identified.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
